stem cell biotech

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

Peter-Marks-Regenerative-Medicine-Advanced-Therapy-Designation-RMAT-

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm …

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »

20 predictions for stem cells & regenerative medicine in 2018

stem-cell-crystal-ball-300x3001

Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of what I’m hearing through the grapevine, stuff I’m reading, some info that is not yet in the public domain, …

20 predictions for stem cells & regenerative medicine in 2018 Read More »

Mesoblast gets FDA RMAT; List of 10 total designations so far

Mesoblast-e1514313188176

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting …

Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse …

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

What is your favorite stem cell/regen med biotech & why?

stem cell stocks

I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly comprehensive. I’m also curious what readers think are the most promising ones and why. So weigh in with comments please or …

What is your favorite stem cell/regen med biotech & why? Read More »

Mesoblast stock on hold: Poll if you expect good or bad news

Mesoblast_Ltd

Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is expected to run from June 1 to June 10. Mesoblast will announce ““material corporate developments with respect to certain assets …

Mesoblast stock on hold: Poll if you expect good or bad news Read More »

Stem cell company Intellicell facing new financial wrinkles

Intellicell

It’s difficult to make it as a biotech company, I would say stem cell biotechs in general may have an even rougher time, and one such company,  Intellicell (Intellicell Biosciences, Inc), is showing a number of signs of distress in my opinion. An online financial tool predicts the probability of companies going bankrupt within the next …

Stem cell company Intellicell facing new financial wrinkles Read More »